FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Veng-Pedersen

Research Profile

Chemicals & Drugs

Physiology

Pharmacokinetics

Living Beings

Concepts & Ideas

Procedures

Disorders

Anatomy

Reticulocytes

Occupations

Mathematics

Co-author Network

Publications

TOP 3
Izabela Kania-Korwel; Christopher D Barnhart; Mohammed H M E El-Komy; Pamela J Lein; Marianna Stamou; Kim M Truong; Peter Veng-Pedersen; Hans-Joachim Lehmler
2,2',3,5',6-Pentachlorobiphenyl (PCB 95) and its hydroxylated metabolites are enantiomerically enriched in female mice.
Donald M Mock; Demet Nalbant; Mohammad Saleh; Robert L Schmidt; Ronald G Strauss; Peter Veng-Pedersen; Kevin J Freise; Nell I Matthews; Shan Zhu; M Bridget Zimmerman; John A Widness
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease.
Matthew R Rosebraugh; John A Widness; Peter Veng-Pedersen
Multidose optimization simulation of erythropoietin treatment in preterm infants.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Veng-Pedersen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Izabela Kania-Korwel; Christopher D Barnhart; Mohammed H M E El-Komy; Pamela J Lein; Marianna Stamou; Kim M Truong; Peter Veng-Pedersen; Hans-Joachim Lehmler
2,2',3,5',6-Pentachlorobiphenyl (PCB 95) and its hydroxylated metabolites are enantiomerically enriched in female mice.
Environmental science & technology 2012;46(20):11393-401.
2012: Donald M Mock; Demet Nalbant; Mohammad Saleh; Robert L Schmidt; Ronald G Strauss; Peter Veng-Pedersen; Kevin J Freise; Nell I Matthews; Shan Zhu; M Bridget Zimmerman; John A Widness
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease.
Transfusion 2012;52(5):963-73.
2012: Matthew R Rosebraugh; John A Widness; Peter Veng-Pedersen
Multidose optimization simulation of erythropoietin treatment in preterm infants.
Pediatric research 2012;71(4 Pt 1):332-7.
2011: C W Lin; J H Warram; Peter Veng-Pedersen
A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.
Journal of pharmacokinetics and pharmacodynamics 2011;38(5):563-79.
2011: Mohammed H El-Komy; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
Biopharmaceutics & drug disposition 2011;32(5):276-88.
2011: Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(7):1214-20.
2011: Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.
Biopharmaceutics & drug disposition 2011;32(3):131-9.
2011: Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(4):603-9.
2010: Donald M Mock; Nell I Matthews; Shan Zhu; Leon F Burmeister; M Bridget Zimmerman; Ronald G Strauss; Robert L Schmidt; Demet Nalbant; Kevin J Freise; Peter Veng-Pedersen; John A Widness
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotin.
Transfusion 2010;50(12):2553-64.
2010: Lanyi Xie; Robert P Hoffman; Peter Veng-Pedersen
Population analysis of ethnicity and first-phase insulin release.
Diabetes research and clinical practice 2010;89(3):243-9.
2010: Demet Nalbant; Mohammad Saleh; Frederic D Goldman; John A Widness; Peter Veng-Pedersen
Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.
The Journal of pharmacology and experimental therapeutics 2010;333(2):528-32.
2010: Izabela Kania-Korwel; Mohammed H M E El-Komy; Peter Veng-Pedersen; Hans-Joachim Lehmler
Clearance of polychlorinated biphenyl atropisomers is enantioselective in female C57Bl/6 mice.
Environmental science & technology 2010;44(8):2828-35.
2010: Andrew Osei-Bimpong; Mohammad Saleh; Martha Sola-Visner; John Widness; Peter Veng-Pedersen
Correction for effect of cold storage on immature platelet fraction.
Journal of clinical laboratory analysis 2010;24(6):431-3.
2010: Kevin J Freise; John A Widness; Peter Veng-Pedersen
Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.
The Journal of pharmacology and experimental therapeutics 2010;332(1):229-37.
2009: Chih-Wei Lin; Peter Veng-Pedersen
Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.
Journal of pharmacokinetics and pharmacodynamics 2009;36(5):421-41.
2009: Kevin J Freise; Robert L Schmidt; E L Gingerich; Peter Veng-Pedersen; John A Widness
The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time.
International journal of laboratory hematology 2009;31(5):496-504.
2009: Lanyi Xie; Robert P Hoffman; Peter Veng-Pedersen
Noncompartmental pharmacokinetics analysis of glucose-stimulated insulin response in African-American and Caucasian youths.
Biopharmaceutics & drug disposition 2009;30(3):117-25.
2009: Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.
Pediatrics international : official journal of the Japan Pediatric Society 2009;51(1):25-32.
2008: Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
The Journal of pharmacy and pharmacology 2008;60(10):1321-34.
2008: Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.
Journal of pharmacokinetics and pharmacodynamics 2008;35(3):285-323.
2007: N Gupta; Nidal H Al-Huniti; Peter Veng-Pedersen
Individualized pharmacokinetic risk assessment for development of diabetes in high risk population.
Diabetes research and clinical practice 2007;78(1):93-101.
2007: Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.
Pharmaceutical research 2007;24(9):1653-9.
2007: Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.
Journal of pharmacokinetics and pharmacodynamics 2007;34(4):519-47.
2007: John A Widness; Robert L Schmidt; Raymond J Hohl; Frederick D Goldman; Nidal H Al-Huniti; Kevin J Freise; Peter Veng-Pedersen
Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
Clinical pharmacology and therapeutics 2007;81(6):873-9.
2006: Teresa L Warwood; Robin K Ohls; Diane K Lambert; E A Leve; Peter Veng-Pedersen; Robert D Christensen
Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates.
Journal of perinatology : official journal of the California Perinatal Association 2006;26(10):636-9.
2006: Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
A 'bottom-up' approach for endo-PK/PD analysis.
Biopharmaceutics & drug disposition 2006;27(7):313-27.
2006: N Gupta; Robert P Hoffman; Peter Veng-Pedersen
Pharmacokinetic/pharmacodynamic insulin-glucose analysis for differentiation of beta-cell function: an 18 month follow-up study in pre-pubertal lean and obese children.
Biopharmaceutics & drug disposition 2006;27(6):257-65.
2006: Teresa L Warwood; Robin K Ohls; Diane K Lambert; C Jones; Scott H Scoffield; N Gupta; Peter Veng-Pedersen; Robert D Christensen
Intravenous administration of darbepoetin to NICU patients.
Journal of perinatology : official journal of the California Perinatal Association 2006;26(5):296-300.
2006: Lakshmi Durairaj; Srividya Neelakantan; Janice Launspach; Janet L Watt; Margaret M Allaman; William R Kearney; Peter Veng-Pedersen; Joseph Zabner
Bronchoscopic assessment of airway retention time of aerosolized xylitol.
Respiratory research 2006;7():27.
2005: Teresa L Warwood; Robin K Ohls; Susan E Wiedmeier; Diane K Lambert; Cory Jones; Scott H Scoffield; Gupta Neeraj; Peter Veng-Pedersen; Robert D Christensen
Single-dose darbepoetin administration to anemic preterm neonates.
Journal of perinatology : official journal of the California Perinatal Association 2005;25(11):725-30.
2005: Srividya Neelakantan; Peter Veng-Pedersen
Determination of drug absorption rate in time-variant disposition by direct deconvolution using beta clearance correction and end-constrained non-parametric regression.
Biopharmaceutics & drug disposition 2005;26(8):353-70.
2005: N Gupta; Robert P Hoffman; Peter Veng-Pedersen
Pharmacokinetic/pharmacodynamic differentiation of pancreatic responsiveness in obese and lean children.
Biopharmaceutics & drug disposition 2005;26(7):287-94.
2005: Nidal H Al-Huniti; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.
Journal of pharmacokinetics and pharmacodynamics 2005;32(3-4):359-76.
2004: Nidal H Al-Huniti; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Erythropoietin production rate in phlebotomy-induced acute anemia.
Biopharmaceutics & drug disposition 2004;25(9):389-97.
2004: Anne Grete Bechensteen; Sunny Chapel; Peter Veng-Pedersen; John A Widness
Posttransfusion recovery of stored red blood cells in very low birth weight infants using a hemoglobin balance model.
Transfusion 2004;44(7):1019-24.
2004: Nidal H Al-Huniti; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia.
The Journal of pharmacology and experimental therapeutics 2004;310(1):202-8.
2004: Peter Veng-Pedersen; Sunny Chapel; Nidal H Al-Huniti; Robert L Schmidt; Erin Sedars; Raymond J Hohl; John A Widness
Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Biopharmaceutics & drug disposition 2004;25(4):149-56.
2003: Peter Veng-Pedersen; Sunny Chapel; Nidal H Al-Huniti; Robert L Schmidt; Erin Sedars; Raymond J Hohl; John A Widness
A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.
The Journal of pharmacology and experimental therapeutics 2003;306(2):532-7.
2002: Peter Veng-Pedersen; Sunny Chapel; Robert L Schmidt; Nidal H Al-Huniti; Robert T Cook; John A Widness
An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.
Pharmaceutical research 2002;19(11):1630-5.
2001: Sunny Chapel; Peter Veng-Pedersen; Raymond J Hohl; Robert L Schmidt; E M McGuire; John A Widness
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
The Journal of pharmacology and experimental therapeutics 2001;298(2):820-4.
2001: Peter Veng-Pedersen
Noncompartmentally-based pharmacokinetic modeling.
Advanced drug delivery reviews 2001;48(2-3):265-300.
2001: Sunny Chapel; Peter Veng-Pedersen; Robert L Schmidt; John A Widness
Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
Experimental hematology 2001;29(4):425-31.
2000: Sunny Chapel; Peter Veng-Pedersen; Robert L Schmidt; John A Widness
A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.
The Journal of pharmacology and experimental therapeutics 2000;295(1):346-51.
2000: Peter Veng-Pedersen; Jogarao V S Gobburu; Marvin C Meyer; Arthur B Straughn
Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach.
Biopharmaceutics & drug disposition 2000;21(1):1-6.
1999: Peter Veng-Pedersen; John A Widness; L M Pereira; Robert L Schmidt; L S Lowe
A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans.
Biopharmaceutics & drug disposition 1999;20(4):217-23.
1998: Peter Veng-Pedersen; S S Hong; John A Widness; Robert L Schmidt
Correction for non-ideal tracer pharmacokinetic disposition by disposition decomposition analysis (DDA).
Pharmaceutical research 1998;15(9):1469-73.
1997: Peter Veng-Pedersen; John A Widness; J Wang; Robert L Schmidt
A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.
Journal of pharmacokinetics and biopharmaceutics 1997;25(5):569-93.
1996: John A Widness; Peter Veng-Pedersen; Robert L Schmidt; L S Lowe; J A Kisthard; C Peters
In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
The Journal of pharmacology and experimental therapeutics 1996;279(3):1205-10.
1996: Peter Veng-Pedersen
Alternatives to structural modeling.
Methods and findings in experimental and clinical pharmacology 1996;18 Suppl C():49-50.
1996: John A Widness; Peter Veng-Pedersen; C Peters; L M Pereira; Robert L Schmidt; L S Lowe
Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects.
Journal of applied physiology (Bethesda, Md. : 1985) 1996;80(1):140-8.
1995: J A Wilhelm; Peter Veng-Pedersen; T B Zakszewski; E Osifchin; S J Waters
Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
International journal of clinical pharmacology and therapeutics 1995;33(10):540-5.
1995: Peter Veng-Pedersen; J A Wilhelm; T B Zakszewski; E Osifchin; S J Waters
Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
Journal of pharmaceutical sciences 1995;84(9):1101-6.
1995: Peter Veng-Pedersen; John A Widness; L M Pereira; C Peters; Robert L Schmidt; L S Lowe
Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans.
Journal of pharmaceutical sciences 1995;84(6):760-7.
1994: R A Herman; Peter Veng-Pedersen
Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series.
Journal of pharmaceutical sciences 1994;83(3):423-8.
1994: N B Modi; Peter Veng-Pedersen
Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits.
Journal of pharmaceutical sciences 1994;83(3):351-6.
1994: R A Herman; Peter Veng-Pedersen; J Miotto; J Komorowski; G Patrick Kealey
Pharmacokinetics of morphine sulfate in patients with burns.
The Journal of burn care & rehabilitation 1994;15(2):95-103.
1994: N B Modi; Peter Veng-Pedersen; Dale Eric Wurster; MJ Berg; D D Schottelius
Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approach.
Pharmaceutical research 1994;11(2):318-23.
1994: N B Modi; Peter Veng-Pedersen
Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.
Pharmaceutical research 1994;11(1):128-35.
1993: Peter Veng-Pedersen; N B Modi
Application of neural networks to pharmacodynamics.
Journal of pharmaceutical sciences 1993;82(9):918-26.
1993: Peter Veng-Pedersen; N B Modi; John A Widness; L M Pereira; Robert L Schmidt; Michael K Georgieff
A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemia.
Journal of pharmaceutical sciences 1993;82(8):804-7.
1993: N B Modi; Peter Veng-Pedersen; D J Graham; R J Dow
Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males.
Journal of pharmaceutical sciences 1993;82(7):705-13.
1993: Peter Veng-Pedersen; N B Modi
A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil.
Journal of pharmaceutical sciences 1993;82(3):266-72.
1992: Peter Veng-Pedersen; N B Modi
Pharmacodynamic system analysis of the biophase level predictor and the transduction function.
Journal of pharmaceutical sciences 1992;81(9):925-34.
1992: Peter Veng-Pedersen; N B Modi
Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?
Journal of pharmacokinetics and biopharmaceutics 1992;20(4):397-412; discussion 413-8.
1992: John A Widness; Peter Veng-Pedersen; N B Modi; Robert L Schmidt; D H Chestnut
Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep.
The Journal of pharmacology and experimental therapeutics 1992;261(3):977-84.
1992: John A Widness; Robert L Schmidt; Peter Veng-Pedersen; N B Modi; S T Sawyer
A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.
The Journal of laboratory and clinical medicine 1992;119(3):285-94.
1992: Peter Veng-Pedersen; N B Modi
An algorithm for constrained deconvolution based on reparameterization.
Journal of pharmaceutical sciences 1992;81(2):175-80.
1992: G M Burke; Dale Eric Wurster; MJ Berg; Peter Veng-Pedersen; D D Schottelius
Surface characterization of activated charcoal by X-ray photoelectron spectroscopy (XPS): correlation with phenobarbital adsorption data.
Pharmaceutical research 1992;9(1):126-30.
1991: Peter Veng-Pedersen
Reparameterization to implementing kinetic constraints in pharmacokinetics.
Journal of pharmaceutical sciences 1991;80(10):978-85.
1991: Peter Veng-Pedersen; J W Mandema; M Danhof
Biophase equilibration times.
Journal of pharmaceutical sciences 1991;80(9):881-6.
1991: Peter Veng-Pedersen; N B Modi
Optimal extravascular dosing intervals.
Journal of pharmacokinetics and biopharmaceutics 1991;19(4):405-12.
1991: Peter Veng-Pedersen; J G Wagner
Exact dosing times calculations in linear pharmacokinetics.
Journal of pharmaceutical sciences 1991;80(8):805-9.
1991: Peter Veng-Pedersen
Stochastic interpretation of linear pharmacokinetics: a linear system analysis approach.
Journal of pharmaceutical sciences 1991;80(7):621-31.
1991: Peter Veng-Pedersen; J W Mandema; M Danhof
A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.
Journal of pharmaceutical sciences 1991;80(5):488-95.
1991: G M Burke; Dale Eric Wurster; V Buraphacheep; MJ Berg; Peter Veng-Pedersen; D D Schottelius
Model selection for the adsorption of phenobarbital by activated charcoal.
Pharmaceutical research 1991;8(2):228-31.
1990: Daniel E Furst; R A Herman; R Koehnke; N Ericksen; L Hash; C E Riggs; A Porras; Peter Veng-Pedersen
Effect of aspirin and sulindac on methotrexate clearance.
Journal of pharmaceutical sciences 1990;79(9):782-6.
1989: Peter Veng-Pedersen
Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).
Clinical pharmacokinetics 1989;17(6):424-40.
1989: Peter Veng-Pedersen
Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I).
Clinical pharmacokinetics 1989;17(5):345-66.
1989: Peter Veng-Pedersen; L G Tillman
Center of gravity of drug level curves: a model-independent parameter useful in bioavailability studies.
Journal of pharmaceutical sciences 1989;78(10):848-54.
1989: Peter Veng-Pedersen
Mean time parameters dealing with the tissue distribution of drugs: limitations and extensions.
Journal of pharmaceutical sciences 1989;78(3):264-6.
1989: R A Herman; Peter Veng-Pedersen; J Hoffman; R Koehnke; Daniel E Furst
Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.
Journal of pharmaceutical sciences 1989;78(2):165-71.
1988: Peter Veng-Pedersen
Response to commentaries to "Linear and Nonlinear System Approaches in Pharmacokinetics. How much do they have to offer"?
Journal of pharmacokinetics and biopharmaceutics 1988;16(6):686-94.
1988: R A Herman; Peter Veng-Pedersen
A note regarding curve fitting with a sum of exponentials.
Biopharmaceutics & drug disposition 1988;9(6):579-86.
1988: Peter Veng-Pedersen
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.
Journal of pharmacokinetics and biopharmaceutics 1988;16(5):543-71.
1988: Peter Veng-Pedersen
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.
Journal of pharmacokinetics and biopharmaceutics 1988;16(4):413-72.
1988: Dale Eric Wurster; G M Burke; MJ Berg; Peter Veng-Pedersen; D D Schottelius
Phenobarbital adsorption from simulated intestinal fluid, U.S.P., and simulated gastric fluid, U.S.P., by two activated charcoals.
Pharmaceutical research 1988;5(3):183-6.
1988: Peter Veng-Pedersen
System approaches in pharmacokinetics: II. Applications.
Journal of clinical pharmacology 1988;28(2):97-104.
1988: Peter Veng-Pedersen; W R Gillespie
A system approach to pharmacodynamics. I: Theoretical framework.
Journal of pharmaceutical sciences 1988;77(1):39-47.
1988: Peter Veng-Pedersen
System approaches in pharmacokinetics: I. Basic concepts.
Journal of clinical pharmacology 1988;28(1):1-5.
1988: W R Gillespie; Peter Veng-Pedersen; E J Antal; J P Phillips
A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.
Journal of pharmaceutical sciences 1988;77(1):48-55.
1987: T W Rooney; A Lorber; Peter Veng-Pedersen; R A Herman; R Meehan; J Hade; A Hade; Daniel E Furst
Gold pharmacokinetics in breast milk and serum of a lactating woman.
The Journal of rheumatology 1987;14(6):1120-2.
1987: Peter Veng-Pedersen; W R Gillespie
Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. IV. Exact relationship between the terminal log-linear slope parameter beta and drug clearance.
Journal of pharmacokinetics and biopharmaceutics 1987;15(3):305-25.
1987: Peter Veng-Pedersen; W R Gillespie
Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.
Journal of pharmacokinetics and biopharmaceutics 1987;15(3):281-304.
1986: W R Gillespie; Peter Veng-Pedersen; MJ Berg; D D Schottelius
Linear systems approach to the analysis of an induced drug removal process. Phenobarbital removal by oral activated charcoal.
Journal of pharmacokinetics and biopharmaceutics 1986;14(1):19-28.